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ABSTRACT
Genomic loss of chromosome (chr) 8p21 region, containing prostate-specific 
NKX3.1 gene, is a frequent alteration of the prostate cancer (PCa) oncogenome. We 
propose a novel, paradigm shifting hypothesis that this frequently deleted locus is also 
associated with a cluster of microRNA genes- miR-3622a/b- that are lost in PCa and 
play an important mechanistic role in progression and metastasis. In this study, we 
demonstrate the role of miR-3622b in prostate cancer. Expression analyses in a cohort 
of PCa clinical specimens and cell lines show that miR-3622b expression is frequently 
lost in prostate cancer. Low miR-3622b expression was found to be associated with 
tumor progression and poor biochemical recurrence-free survival. Further, our 
analyses suggest that miR-3622b expression is a promising prostate cancer diagnostic 
biomarker that exhibits 100% specificity and 66% sensitivity. Restoration of miR-
3622b expression in PCa cell lines led to reduced cellular viability, proliferation, 
invasiveness, migration and increased apoptosis. miR-3622b overexpression in 
vivo induced regression of established prostate tumor xenografts pointing to its 
therapeutic potential. Further, we found that miR-3622b directly represses Epidermal 
Growth Factor Receptor (EGFR). In conclusion, our study suggests that miR-3622b 
plays a tumor suppressive role and is frequently downregulated in prostate cancer, 
leading to EGFR upregulation. Importantly, miR-3622b has associated diagnostic, 
prognostic and therapeutic potential. Considering the association of chr8p21 loss 
with poor prognosis, our findings are highly significant and support a novel concept 
that associates a long standing observation of frequent loss of a chromosomal region 
with a novel miRNA in prostate cancer.
INTRODUCTION
Prostate cancer (PCa) is the most common male 
malignancy worldwide and a leading cause of cancer 
related mortality amongst men [1, 2] with an estimated 
26,120 deaths predicted for 2016 within the US [2]. 
Prostate tumors are often indolent and can be effectively 
managed by active surveillance and watchful waiting [3, 
4]. However, a significant proportion of prostate tumors 
are likely to progress, often metastasizing to bone and 
other organs causing significant morbidity and mortality 
[5]. Though novel therapies with marginal survival 
benefits have been developed for advanced disease [6, 
7], its clinical management remains challenging. Also, 
PCa is associated with high rates of recurrence, with 
approximately 40% of men with localized PCa suffering 
from relapse after initial therapy [8] as monitored by rising 
PSA and tumor progression to a hormone refractory/
castration resistant stage [1, 9] that is essentially 
untreatable [1, 10]. A major challenge is the elucidation 
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of underlying molecular pathways of PCa progression, 
recurrence and metastasis that holds enormous potential 
towards the design of effective therapeutic strategies for 
better clinical management of the disease.
The prostate cancer genome is typically 
characterized by frequent deletion of chromosome 
8p (chr8p) region in 40%-70% cases [11–17]. Taylor 
et al. performed large scale integrative analyses of 
transcriptomes and copy-number alterations (CNAs) in 
prostate adenocarcinomas and reported chr8p loss as the 
most frequent genomic alteration [17]. In a recent in silico 
meta analyses of PCa genomic data from 662 patients 
(546 primary, 116 advanced tumors), chr8p deletion was 
reported as the most recurrent CNA [18]. Chr8p losses 
were reported in 55.7% cases of localized and 90.5% 
cases of advanced PCa [18]. Association of advanced 
PCa with a significantly higher deletion frequency of 
this region [19] suggests its role in disease progression. 
The minimal region of deletion occurs at chr8p21 [18], 
which contains prostate-specific NKX3.1 tumor suppressor 
gene [20]. Also, studies have shown high rate of loss of 
heterozygosity (LOH) at chr8p21 subregion [21, 22] that 
has been associated with prostate-specific homeobox 
gene NKX3.1 [20]. Recent genomic studies suggest the 
possibility of alternate tumor suppressor genes within 
this region, apart from NKX3.1 [17]. However, the genes 
within this region are yet to be fully characterized. We 
propose a novel, paradigm shifting hypothesis that this 
frequently deleted locus is associated with a cluster of 
microRNA genes- miR-3622a/b- that are lost in PCa and 
play an important mechanistic role in PCa progression and 
metastasis. MicroRNAs (miRNAs) are endogenous small 
RNAs that suppress gene expression post transcriptionally 
via sequence-specific interactions with the 3’- untranslated 
regions (UTRs) of cognate mRNA targets [23], and are 
often located in fragile chromosomal regions involved 
in cancers [24]. We previously demonstrated that miR-
3622a located on frequently deleted chr8p21 region plays 
a crucial role in PCa epithelial-to-mesenchymal transition 
(EMT), progression and metastasis by direct targeting 
of ZEB1 and SNAI2 (Bucay et al., manuscript under 
consideration). Here we examined the role of another 
member of the cluster- miR-3622b- in PCa and show its 
crucial tumor suppressive role. miR-3622b is a recently 
discovered miRNA gene [25] that has not been studied. 
Expression analyses in a cohort of PCa clinical specimens 
showed that miR-3622b expression is frequently lost in 
PCa and correlated with poor recurrence-free survival 
outcome and tumor progression. Our in vitro and in vivo 
studies support a tumor suppressive role of miR-3622b in 
PCa, mediating its effects largely by directly repressing 
Epidermal Growth Factor Receptor (EGFR). Thus, our 
data support a novel concept, linking the long standing 
observation of frequent loss of chr8p21 in PCa, with the 
loss of a novel miRNA gene within this region.
RESULTS
MicroRNA-3622b located in frequently deleted 
chr8p21 region is underexpressed in prostate 
cancer
Along with the NKX3.1 gene [25, 26], frequently lost 
Chr8p21 region contains a cluster of miRNA genes- miR-
3622a and miR-3622b (Figure 1A). We analyzed CNAs 
at the miR-3622b locus in prostate adenocarcinomas in 
The Cancer Genome Atlas (TCGA) dataset (n=187) [27, 
28]. Similar to miR-3622a, miR-3622b locus was deleted 
either homozygously or heterozygously in ~ 50% cases 
suggesting that prostate tumors are associated with a 
frequent genomic deletion of this miRNA (Figure 1B). 
Based on this, we hypothesized that miR-3622b expression 
is lost in PCa and may underlie prostate carcinogenesis. 
To test our hypothesis, we first performed miR-3622b-5p 
(referred to as miR-3622b) expression profiling in a large 
cohort of PCa clinical specimens (n=100) and matched 
adjacent normal regions by real-time PCR (Figure 1C). 
miR-3622b expression was significantly downregulated in 
~66% of PCa cases (Wilcoxon Signed Rank test P-value < 
0.0001). 13% of PCa cases showed no change and ~21% 
cases exhibited high expression. Patients’ demographics 
and clinicopathological characteristics are summarized 
in Table 1. We also analyzed miR-3622b expression in 
prostate cell lines (Figure 1D) showing that its expression 
is specifically attenuated in PCa cell lines (PC3, DU145, 
LNCaP, LAPC4, LAPC9) compared to BPH1 cell line. 
These data point to the widespread attenuated expression 
of miR-3622b in PCa.
Low miR-3622b expression is associated with 
tumor progression and biochemical recurrence 
in prostate cancer
In view of the observed widespread low miR-
3622b expression in PCa clinical tissues, we evaluated 
the correlation of miR-3622b expression with 
clinicopathological parameters of the disease (Figure 
2A). While no correlation was observed between miR-
3622b expression and age, low miR-3622b expression 
was observed in 57% cases of Gleason 6, 69% cases 
of Gleason 7 (3+4), 86% of Gleason 7 (4+3) and 90% 
cases of Gleason 8-10. Similarly, decreased miR-3622b 
expression was observed in 63% of cases of pathological 
stage pT2, 71% of cases of pT3 and 100% of pT4 
cases. This trend suggests that miR-3622b expression 
is progressively downregulated in tumors with higher 
Gleason grade and stage though this correlation failed to 
reach statistical significance. Interestingly, statistically 
significant correlation was observed between low miR-
3622b expression and biochemical recurrence (BCR). 
Kaplan-Meier survival analysis for recurrence-free 
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survival (RFS) (Figure 2B) showed that cases with 
low miR-3622b expression had a significantly lower 
recurrence-free survival probability than those with high 
expression (P=0.0321). Also, cases with low miR-3622b 
expression had lower overall survival probability (Figure 
2C) as compared to high expressors though this result was 
statistically insignificant with the present cohort.
Low miR-3622b expression is correlated with 
high serum PSA in prostate cancer
We observed significant inverse correlation between 
miR-3622b expression and serum PSA levels (P=0.0292) 
(Figure 2A). Low miR-3622b expression was observed 
in 47% of PCa cases with low PSA and in 75% of cases 
with high PSA levels. We also analyzed this correlation 
using age-adjusted PSA values (Figure 3A) and found 
that miR-3622b expression is statistically correlated 
with age-adjusted PSA levels (P= 0.0404). In view of 
these results, we performed ROC analyses to test the 
diagnostic potential of miR-3622b expression (Figure 
3B). This analyses showed that miR-3622b expression 
can be a single significant parameter to discriminate 
between normal and tumor tissues with AUC of 0.924 
(95% CI: 0.883-0.955, P<0.0001). The discriminatory 
ability of miR-3622b as a diagnostic classifier was further 
characterized. Our analyses showed that miR-3622b as a 
diagnostic biomarker exhibits a specificity of 1, sensitivity 
of 0.66, positive predictive value of 1.0 and negative 
predictive value of 0.75 (Figure 3C). Overall, our analyses 
suggest that miR-3622b has significant potential as a 
diagnostic biomarker for PCa.
miR-3622b overexpression suppresses 
tumorigenicity in vitro in prostate cancer cell 
lines
In view of low miR-3622b expression levels in PCa 
clinical specimens and PCa cell lines, we evaluated the 
tumor suppressive potential of miR-3622b overexpression 
in vitro and in vivo. miR-3622b overexpression 
(Supplementary Figure S1) in PCa cell lines PC3, LNCaP 
and Du145 led to reduced cellular viability (Figure 4A) as 
compared to control miRNA (miR-CON) transfected cells. 
Figure 1: MicroRNA-3622b located in frequently deleted chr8p21 region is under expressed in prostate cancer. A. 
Schematic representation of chr8p21 region highlighting the location of miR-3622a/b cluster. miR-3622b is located at position 27701673-
27701767 on the antisense strand. B. CNAs at miR-3622b locus in the TCGA cohort of prostate adenocarcinomas. C. miR-3622b expression 
levels in PCa specimens relative to matched adjacent normals as assessed by real-time PCR. D. Relative miR-3622b expression levels in 
immortalized non-malignant cell line (BPH1) and PCa cell lines as assessed by RT-PCR. Data were normalized to RNU48 control. (*P< .05).
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Table 1: Clinicopathologic characteristics of prostate cancer patients (N = 100)
Characteristics Number of patients N(%)
Age, Years*  
 Mean 62.5
 Median 62
 Range 47-79
T-stage**  
 pT2 3 (3)
 pT2a 12 (12)
 pT2b 15 (15)
 pT2c 34 (34)
 pT3 1 (1)
 pT3a 15 (15)
 pT3b 5 (5)
 pT4 1 (1)
Gleason Score***  
 6 53 (53)
 7 33 (33)
 8-10 10 (10)
PSA****  
 Median 4.7
 <4.7 32 (32)
 >4.7 59 (59)
PSA failure 35
N-stage  
 N0/NX 100 (100)
M-stage  
 M0/MX 100 (100)
Pathological diagnosis  
 Adenocarcinoma 100 (100)
*No information on age for 3 cases
** Tumor stage unknown for 14 cases
*** Gleason score unknown for 4 cases
**** PSA values not known for 9 cases
Clinicopathological characteristics of prostate cancer clinical tissues used for real-time PCR analysis of miR-3622b 
expression. T-stage refers to the pathological stage of the primary tumor, ranging from pT2 to pT4. N-stage indicates if 
the cancer has spread to nearby regional lymph nodes where NX refer to cases with lymph nodes not assessed and N0 
denotes cases with tumor not spread to nearby lymph nodes. M-stage refers to metastasis to distant organs wherein M0 
denotes absence of metastasis and MX denotes cases with metastasis not assessed. Gleason score indicates the grade 
or differentiation of primary tumors ranging from well-differentiated or low grade (cancers with a Gleason score of 6) 
to moderately-differentiated (Gleason score 7) or high grade or poorly differentiated (Gleason scores of 8-10) tumors. 
Additional parameters include serum PSA levels at the time of diagnosis and PSA failure/biochemical recurrence.
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miR-3622b overexpression decreased the clonogenicity 
(Figure 4B), migration and invasiveness (Figure 4C) of 
PC3/LNCaP/Du145 cells. These observations demonstrate 
that miR-3622b overexpression suppresses the in vitro 
attributes of tumorigenicity in PCa cell lines.
miR-3622b overexpression induces apoptosis in 
PCa cell lines
miR-3622b overexpression led to marked 
morphological changes in PCa cell lines with the 
cells transitioning from an elongated, spindle shaped 
morphology to rounded, apoptotic cells suggesting that 
miR-3622b overexpression leads to induction of apoptosis. 
To confirm this, we performed flow cytometric analysis 
of Annexin-V-FITC-7-AAD stained LNCaP/Du145/PC3 
cells transfected with miR-CON/miR-3622b (Figure 
5A-5C). It was observed that the average apoptotic cell 
fractions (early apoptotic + apoptotic) were significantly 
(P=0.026) increased with a concomitant decrease in the 
viable cell populations upon miR-3622b overexpression 
in PCa cell lines compared to miR-CON transfected cells. 
These analyses suggest that miR-3622b affects apoptotic 
pathways in PCa and plays a pro-apoptotic role. In line 
with these data, we found that miR-3622b overexpresssion 
induces poly-ADP-ribose polymerase (PARP) cleavage in 
PCa cell lines (Supplementary Figure S2).
Intratumoral delivery of miR-3622b leads to 
tumor regression in PCa xenografts
In view of the tumor suppressive effects of miR-
3622b overexpression observed in vitro, we examined the 
therapeutic potential of miR-3622b in a PCa xenograft 
mouse model (Figure 6). PC3 cells were subcutaneously 
injected into nude mice and maintained until solid, 
Figure 2: Low miR-3622b expression is associated with biochemical recurrence in prostate cancer. A. Correlation of 
miR-3622b expression with clinicopathological characteristics of prostate cancer patient cohort. P-values based on a Chi square test. B. 
Kaplan-Meier survival analysis for recurrence-free survival (RFS) of PCa patients, stratified based on miR-3622b levels. P-value based 
on a log rank test. C. Kaplan-Meier analyses for overall survival of PCa patients, stratified based on miR-3622b levels. P-value based on 
a log rank test.
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palpable tumors were formed. Control miRNA or miR-
3622b mimics were injected intratumorally at periodic 
intervals and tumor growth was monitored regularly. 
Interestingly, we observed a significant tumor growth 
inhibition in mice injected with miR-3622b mimics 
supporting the tumor suppressive effects of this miRNA 
in PCa (Figure 6A-6B). To confirm that the observed 
tumor regression was correlated to miR-3622b delivery, 
we harvested the tumors from control or miR-3622b 
(n=5) groups followed by RNA extractions and real time 
PCR based analyses of miR-3622b levels (Figure 6C). 
miR-3622b expression was significantly higher in tumors 
injected with synthetic miR-3622b versus control tumors.
miR-3622b targets Epidermal Growth Factor 
Receptor in prostate cancer
To identify miR-3622b targets, we performed in 
silico analyses followed by Western blotting of potential 
miR-3622b targets. Our analyses identified that miR-3622b 
represses Epidermal Growth Factor Receptor (EGFR) and 
polycomb repressor BMI1 in PCa cell lines (Figure 7A and 
Supplementary Figure S3). Immunoblotting of mock/miR-
CON/miR-3622b overexpressing PC3/LNCaP/Du145 cells 
confirmed that miR-3622b represses EGFR protein levels 
in all cell lines (Figure 7A). Also, miR-3622b inhibited 
the expression of BMI1, primarily in LNCaP/Du145 cell 
lines. The 3’ UTR region of EGFR possess three potential 
miR-3622b binding sites while that of BMI1 has 1 site 
(Figure 7B and Supplementary Figure S3A). Due to the 
modest effects on BMI1 expression observed in PC3 
cells, we focused on EGFR as a target. To verify that the 
repressive effects on EGFR expression are as a result of 
direct interaction of miR-3622b with the corresponding 
microRNA binding sites within EGFR 3’ UTR, we 
constructed luciferase reporter vectors with potential miR-
3622b sites 1-3. EGFR 3’ UTR possesses two 7mer-m8 
sites and one 7mer-A1 site (Figure 7B) [29, 30]. To 
further validate these sites, we mutated the potential miR-
3622b binding sites in EGFR 3’ UTR as represented in 
Figure 7B. Luciferase reporter assays with wt and mutant 
EGFR 3’UTR/Control 3’UTR in miR-CON/miR-3622b 
transfected PC3 cells (Figure 7C) showed that there was 
a decrease in wild type EGFR luciferase reporter activity 
upon miR-3622b overexpression while the mutation of 
the miR-3622b binding sites prevented the repression of 
luciferase activity. Luciferase reporter activity with miR-
3622b binding sites 1 and 2 showed a significant decrease 
while the observed repression with site 3 reporter construct 
was statistically insignificant suggesting that miR-3622b 
represses EGFR predominantly through its direct binding 
to two 7mer-m8 sites within its 3’UTR.
Figure 3: Potential diagnostic utility of miR-3622b expression in prostate cancer. A. Correlation of miR-3622b expression 
with age-adjusted serum PSA levels in PCa patients. (* P< .05). B. ROC curve analysis showing the ability of miR-3622b expression to 
discriminate between malignant and non-malignant cases. C. Diagnostic utility measures of miR-3622a as a prostate cancer biomarker. (* 
P< .05).
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Figure 4: miR-3622b overexpression suppresses tumorigenicity in vitro in prostate cancer cell lines. To assess the 
functional significance of miR-3622b, miR-3622b or a control miR (miR-CON) was overexpressed in PCa cell lines (PC3, LNCaP, Du145) 
by transient transfections followed by functional assays 72 hrs post-transfection (* P< .05). A. Cell viability assays B. Colony formation 
assays C. Transwell migration and invasion assays in PC3/ LNCaP/ Du145 cells transfected with mock/ miR-CON/ miR-3622b.
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Figure 5: miR-3622b overexpression induces apoptosis in prostate cancer cell lines. Flow cytometric analysis of Annexin-V-
FITC-7-AAD stained A. LNCaP, B. Du145 and C. PC3 transfected with miR-CON/ miR-3622b.
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EGFR knockdown partially phenocopies miR-
3622b overexpression in LNCaP cells
To determine if EGFR represents a functionally 
relevant target of miR-3622b in PCa, we looked to see 
if EGFR knockdown functionally mimics the effects 
of miR-3622b overexpression in PCa. Towards this, 
we performed siRNA mediated-EGFR knockdown in 
LNCaP cells followed by functional assays (Figure 7E-
7G). We initially tested three sets of siRNAs (siRNA-A, 
siRNA-B, siRNA-C) against EGFR and assessed the 
knockdown efficiency by RT-PCR analyses (Figure 7D, 
left panel). siRNA-A and siRNA-B were effective in 
knocking down EGFR expression by ~70% as compared 
to negative control scrambled siRNA (NS) and were used 
in subsequent experiments. Immunoblotting analyses 
confirmed knockdown of EGFR protein levels after 
siRNA-A and -B treatment (Figure 7D, right panel). EGFR 
inhibition led to decreased cellular viability (Figure 7E), 
migration and invasiveness of LNCaP cells (Figure 7F). 
Also, apoptotic cell fractions (early apoptotic + apoptotic) 
were significantly increased upon EGFR knockdown as 
compared to NS siRNA, an effect similar to that observed 
upon miR-3622b overexpression in LNCaP cells (Figure 
7G). These results suggest that EGFR inhibition partially 
phenocopies the effects of miR-3622b overexpression in 
the LNCaP cell line.
DISCUSSION
Loss of chromosome 8p [11–17]- particularly 
chr8p21 subregion- [21, 22] – has been consistently 
reported as a frequent alteration of the PCa genome that 
has been associated with the loss of tumor suppressors such 
as prostate-specific NKX3.1 gene [20]. Our study uncovers 
the role of a novel alternative tumor suppressor miRNA 
gene- miR-3622b- in this region that plays a crucial role 
in PCa by regulating EGFR. miR-3622b is a member of 
the miR-3622a/b cluster located within the chr8p21 region 
Figure 6: Intratumoral delivery of miR-3622b leads to tumor regression in PCa xenografts. PC3 cells were subcutaneously 
injected into nude mice and maintained until solid, palpable tumors (Day 30), following which control miRNA/ miR-3622b mimics were 
injected intratumorally at periodic intervals (indicated) and tumor growth was monitored. (* P< .05). A. Tumor volumes following miR-
CON/miR-3622b administration at the indicated time points. B. Representative images of mice from the two groups on day 54 are shown. 
C. Relative miR-3622b expression in PCa xenografts as assessed by real-time PCR.
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Figure 7: miR-3622b targets Epidermal Growth Factor Receptor in prostate cancer. A. Immunoblots of endogenous EGFR 
and BMI1 in PC3 (left panels), LNCaP (middle panels) and Du145 cells (right panels) transfected with mock/miR-CON/miR-3622b. 
GAPDH was used a loading control. B. Schematic representation of the EGFR 3’-UTR showing the putative miR-3622b binding sites. 
Respective mutant EGFR sites are represented below. C. Luciferase reporter assays with the indicated wt and mutant EGFR 3’ UTR 
constructs or control luciferase construct co-transfected with miR-CON/ miR-3622b in PC3 cells. Firefly luciferase values were normalized 
to Renilla luciferase activity and plotted as relative luciferase activity (* P< .05). D. LNCaP cells were transfected with three sets of siRNAs 
(siRNA-A, siRNA-B, siRNA-C) against EGFR or a nonspecific (NS) control siRNA/mock transfected for 72 h (*P< .05) followed by 
functional assays. Left panel: Real time PCR analyses of relative EGFR expression. Data were normalized to GAPDH control. siRNA-A 
and siRNA-B were effective in knocking down EGFR expression by ~70% as compared to NS and were used in subsequent experiments. 
Right panel: Immunoblot analyses for EGFR protein expression after NS/EGFR siRNA transfections. GAPDH was used as a loading 
control. E. Cellular viability assay, F. Transwell migration and invasion assay after NS/EGFR siRNA- A and siRNA-B transfections. G. 
Apoptosis assay upon NS siRNA (left panel) or EGFR siRNA-A (middle panel) or siRNA-B (right panel) transfections.
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[25]. Our earlier study demonstrated an important role 
of miR-3622a in PCa EMT, progression and metastasis 
(Bucay et al., manuscript under consideration). Studies 
show a significant increase in chr8p deletions with tumor 
progression and poor prognosis in PCa [31, 32], pointing 
to its important mechanistic role in PCa progression. 
Our studies lend support to this notion. Also, it has been 
suggested that copy number alterations frequently lead 
to loss of multiple genes that may cooperate to produce 
more aggressive disease [33]. Our present study, in 
conjunction with our earlier study on miR-3622a, support 
our hypothesis that a cluster of miRNAs, miR-3622a/b, at 
frequently deleted chr8p21 region are frequently lost in 
PCa leading to tumor progression.
A major challenge in PCa clinical management 
is posed by the lack of robust disease biomarkers for 
accurate diagnosis and prognosis [34–36]. Our analyses 
suggest that miR-3622b expression is widely attenuated in 
PCa clinical specimens and that miR-3622b expression is 
a promising PCa diagnostic biomarker that exhibits 100% 
specificity and 66% sensitivity. Interestingly, miR-3622b 
expression was inversely correlated with age-adjusted 
serum PSA values. In view of these results, we suggest 
miR-3622b as an alternative PCa diagnostic biomarker 
that can be used as a supplement to serum PSA testing. 
Our data also suggests that miR-3622b expression can 
be used to predict biochemical recurrence and low miR-
3622b expression was found to be associated with poor 
biochemical recurrence-free survival. Though we did 
not observe a statistically significant correlation between 
low miR-3622b expression and pathological stage and 
tumor grade, miR-3622b expression was progressively 
lost in advanced tumors. In view of this, further studies 
with larger clinical cohorts are warranted to test the 
prognostic potential of miR-3622b in PCa. Overall, our 
study indicates that miR-3622b has significant potential as 
a diagnostic and prognostic PCa biomarker.
Restoration of miR-3622b expression in PCa 
cell lines led to reduced cellular viability, proliferation, 
invasiveness, migration and increased apoptosis. 
Collectively, these data support a tumor suppressive role 
for miR-3622b in PCa. In keeping with this, injection of 
miR-3622b mimics in established PCa mouse xenografts 
led to tumor regression in vivo suggesting that restoration 
of miR-3622b expression can be an attractive therapeutic 
modality in PCa. An anti-apoptotic role of miR-3622b in 
PCa was indicated by the induction of apoptosis and PARP 
cleavage following its overexpression.
Interestingly, our data suggests that miR-3622b 
directly represses EGFR in prostate cancer. EGFR, a 
tyrosine kinase receptor of the ERBB transmembrane 
growth factor receptor family, plays a key role in major 
cellular processes such as survival, proliferation, invasion 
[37–39]. It is frequently overexpressed in solid tumors 
from various organs, including PCa, causing tumor growth 
and progression and is an important therapeutic target [37–
41]. EGFR expression has been reported to be significantly 
correlated with high tumor grade, advanced stage, high 
risk for PSA recurrence and shorter progression-free 
survival [40]. 100% of cases of metastatic hormone 
refractory PCa express EGFR. In our study, we discovered 
miR-3622b-mediated regulation of EGFR suggesting that 
this regulatory control may underlie the observed effects of 
miR-3622b overexpression on cell survival, proliferation 
and invasion. EGFR knockdown phenocopied the effects 
of miR-3622b overexpression in PCa cell line, lending 
support to our hypothesis. Targeting the EGFR axis is a 
potential therapeutic strategy in prostate cancer [42, 43]. 
The combination of EGFR inhibitor gefitinib and radiation 
has been reported to have promising activity against 
prostate cancer [43]. In view of our results, we propose 
that miR-3622b may be an important anti-cancer target for 
EGFR overexpressing prostate tumors.
In conclusion, our study shows that miR-3622b is 
frequently downregulated in PCa leading to upregulation 
of EGFR and culminating in effects on cell survival, 
proliferation, apoptosis and invasion. In view of our 
present results and our earlier study on miR-3622a, 
we propose that the miR-3622a/b cluster at frequently 
deleted chr8p21 locus plays important mechanistic roles 
in prostate cancer by regulating cardinal genes involved 
in tumorigenesis. Frequent loss of miR-3622a/b cluster 
at chr8p21 region causes downregulation of these genes 
leading to prostate cancer progression. Considering the 
association of chr8p21 loss with tumor progression and 
poor prognosis in prostate cancer [31, 32], our findings 
are highly significant as they support a novel concept that 
connects a long standing observation of frequent loss of 
a chromosomal region with a novel miRNA cluster in 
prostate cancer. Importantly, these miRNAs also have 
prognostic, diagnostic and therapeutic potential in the 
treatment of prostate cancer.
MATERIALS AND METHODS
Ethics statement
Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by San Francisco 
Veteran Affairs Medical Center (SFVAMC) review board.
Cell lines and cell culture
PCa cell lines (PC3, LNCaP, Du145) were obtained 
from the American Type Culture Collection (ATCC) and 
cultured under recommended conditions. PC3, LNCaP 
cell lines were maintained in RPMI 1640 media (UCSF 
cell culture facility) and Du145 cells were cultured in 
MEM media, each supplemented with 10% fetal bovine 
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serum (FBS) (Atlanta biologicals) and 1% penicillin/
streptomycin (UCSF cell culture facility). Immortalized 
non-transformed prostate epithelial cell line (BPH1) 
[44] was maintained in RPMI 1640 media supplemented 
with 5% FBS, and 1% penicillin/streptomycin. All cell 
lines were maintained in an incubator with a humidified 
atmosphere of 95% air and 5% CO2 at 37°C. Prostate 
cell lines were authenticated by DNA short-tandem repeat 
analysis. The experiments with cell lines were performed 
within 6 months of their procurement/resuscitation.
miRNA/siRNA transfections
Cells were plated in growth medium without 
antibiotics ~24 hrs before transfections. Transient 
transfections of miRNA precursor (Ambion) or siRNA 
(Origene) was carried out by using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s protocol. For 
miRNA transfections, miR-3622b precursor (PM20243) or 
negative control (miR-CON) (AM17110) were purchased 
from Ambion. Trilencer-27 predesigned siRNA duplexes 
(SR301357) or universal scrambled negative control 
siRNA duplex (SR30004) purchased from Origene were 
used for siRNA-mediated EGFR knockdown. All miRNA/
siRNA transfections were for 72h.
Tissue samples
Formalin-fixed, paraffin-embedded (FFPE) PCa 
samples were obtained from the SFVAMC. Written 
informed consent was obtained from all patients and the 
study was approved by the UCSF Committee on Human 
Research. All slides were reviewed by a board certified 
pathologist for the identification of PCa foci as well as 
adjacent normal glandular epithelium.
Laser capture microdissection (LCM)
Laser capture microdissection of tumor and adjacent 
normal areas was performed using the AutoPix System 
(Arcturus) as previously described [45, 46]. Briefly, 8μm 
sections were placed on glass slides, deparaffinized, 
stained with hematoxylin, dehydrated, and placed in the 
AutoPix instrument for microdissection. Areas of interest 
were captured with infrared laser pulses onto CapSure 
Macro LCM Caps.
RNA and miRNA extraction
Total RNA was extracted from microdissected 
FFPE tissues using a miRNeasy FFPE Kit (Qiagen). 
A miRNeasy mini kit (Qiagen) was used for miRNA 
extraction from cultured cells and xenograft tumors 
following the manufacturer’s instructions.
Quantitative real-time PCR
Mature miRNAs and mRNAs were assayed 
using the TaqMan MicroRNA Assays and Gene 
Expression Assays, respectively, in accordance with 
the manufacturer’s instructions (Applied Biosystems). 
Samples were normalized to RNU48 or GAPDH (Applied 
Biosystems) controls, as indicated. Taqman assays used 
were hsa-miR-3622b (assay ID 465068_mat), RNU48 
(assay ID 001006), EGFR (Hs01076090_m1), GAPDH 
(Hs99999905_m1), The comparative Ct method was used 
to calculate the relative changes in gene expression on the 
7500 Fast Real Time PCR System.
Cell viability and clonogenicity assays
Cell viability was determined at 24, 48, 72 hours 
by using the CellTiter 96 AQueousOne Solution Cell 
Proliferation Assay Kit (Promega), according to the 
manufacturer’s protocol. For clonogenicity assay, 48 
hrs post-transfection, cells were counted, seeded at low 
density (1000 cells/plate) and allowed to grow until visible 
colonies appeared. Then, cells were stained with Giemsa 
and colonies were counted.
Migration and invasion assays
Cell migration and invasion assay inserts (BD 
Biosciences) were used according to the manufacturer’s 
protocol. Briefly, 48 hrs post-transfection, cells were 
counted and placed on control inserts (for migration) or 
matrigel inserts (for invasion) at 1x105 cells/ml in serum-
free medium and were allowed to migrate at 37°C for 24 
h. After removing the cells from the top of the inserts, cells 
that migrated/invaded though the polycarbonate/basement 
membrane were fixed, stained and quantified at OD 560 
nm after extraction.
Apoptosis assay
Fluorescence-activated cell-sorting (FACS) 
analysis was done 72 hours post-transfection. The cells 
were harvested, washed with cold PBS and stained with 
7-AAD and Annexin-V-FITC using a Annexin-V-FITC 
/7-AAD KIT (Beckman Coulter) for apoptosis analysis 
according to the manufacturer’s protocol. Stained cells 
were immediately analyzed by FACS (Cell Lab Quanta 
SC; Beckman Coulter, Inc).
Western blotting
Whole cell extracts were prepared in RIPA buffer 
[50 mmol/L Tris (pH 8.0), 150 mmol/L NaCl, 0.5% 
deoxycholate, 0.1% SDS, and 1.0% NP-40] containing 
protease inhibitor cocktail (Roche). Total protein was 
electrophoresed by SDS-PAGE and Western blotting 
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was carried out according to standard protocols. The 
following antibodies were used for Western blotting: 
EGFR (Cell Signaling, cat no. 4267), GAPDH (Santa Cruz 
Biotechnology, sc-32233).
Luciferase assays
EGFR 3’UTR region containing potential target 
sequences complementary to the miR-3622b seed 
sequence were cloned downstream of the luciferase gene 
in the pmiRGLO luciferase vector (Promega) according to 
the manufacturer’s instructions. Mutated 3’UTR sequences 
complementary to miR-3622b were cloned in the same 
vector. Primers used for these clonings were synthesized 
by Invitrogen and are listed in Supplementary Table S1. 
3’-UTR EGFR reporter/ control constructs (0.2 ug each) 
in the pmiRGLO luciferase vector (Promega) were each 
cotransfected in PC3 cells with 50 nM miR-CON/ miR-
3622b precursor (Ambion) using Lipofectamine 2000 
(Invitrogen). Firefly and Renilla luciferase activities were 
measured by using the dual luciferase reporter assay 
system (Promega) 48 hr post-transfection in accordance 
with the manufacturer’s protocol. Firefly luciferase was 
normalized to Renilla luciferase activity.
In vivo intratumoral delivery of miR-3622b
All animal care was in accordance with the 
guidelines of the SFVAMC and the study was approved by 
the San Francisco VA IACUC. The therapeutic potential 
of miR-3622b was examined by local administration in 
established tumors in a PCa xenograft mouse model as 
previously described [45, 47, 48]. Nude mice (5 weeks-
old, Simonsen Laboratories) (n=12) were injected with 
2 X 106 PC3 cells (in 100 μl volume) subcutaneously 
in the right flanks. Once palpable tumors developed, 
caliper measurements were taken twice a week and tumor 
volumes were calculated as x2y/2, where width (x) < 
length (y). Synthetic miR-3622b precursor/ miR-CON 
(6.25 μg each) complexed with 1.6 μL siPORTamine 
transfection reagent (Ambion) in a volume of 50 μL PBS 
was delivered intratumorally every 4 days. Synthetic 
miRNAs are double-stranded, ready-to-use miRNA 
precursors and were procured from Ambion (pre-miR, 
cat. no. AM17100). Mice were killed 2 days after the last 
treatment (day 56) and tumors were harvested.
Statistics
All quantified data represents an average of 
triplicate samples or as indicated. Data are represented as 
mean ± S.E.M or as indicated. Two-tailed Student’s t-test 
was used for comparisons between groups. All statistical 
analyses were performed using MedCalc version 10.3.2. 
Results were considered statistically significant at P ≤ 
0.05. The Wilcoxon Signed Rank test was used to assess 
the difference between miR-3622b expression in clinical 
tissues (tumor and normal adjacent). Correlations between 
miR-3622b expression and clinicopathological parameters 
were assessed using Chi squared test. For Kaplan-Meier 
survival analysis, cases were stratified into high (relative 
expression > 1.25)/no change (relative expression 0.75-
1.25) and low expression groups (relative expression 
<0.75) based on miR-3622b expression levels. Receiver 
operating characteristic (ROC) curves were calculated 
to determine the potential of miR-3622b to discriminate 
between malignant and normal samples. miR-3622b 
is modeled as a categorical variable (no change, low 
expression, high expression). Areas under the ROC curve 
(AUC) were estimated and reported with 95% DeLong 
Confidence Intervals (CI). The discriminatory ability of 
miR-3622b expression was further characterized based 
on a dichotomous variable (no change/ high expression 
vs. low expression); using apparent prevalence, true 
prevalence, sensitivity, specificity, positive predictive 
value, negative predictive value, positive likelihood ratio 
and negative likelihood ratio.
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